Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

The New England Journal of Medicine
Deepak L BhattSCORED Investigators

Abstract

The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied. We conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, ≥7%), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m2 of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding. Of 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P...Continue Reading

References

Sep 15, 1994·Statistics in Medicine·T A StukelJ E Wennberg
Jan 13, 2006·JAMA : the Journal of the American Medical Association·Deepak L BhattUNKNOWN REACH Registry Investigators
Mar 22, 2007·JAMA : the Journal of the American Medical Association·Ph Gabriel StegUNKNOWN REACH Registry Investigators
Sep 2, 2010·JAMA : the Journal of the American Medical Association·Deepak L BhattUNKNOWN REACH Registry Investigators
Oct 12, 2010·The New England Journal of Medicine·Deepak L BhattUNKNOWN COGENT Investigators
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Feb 6, 2016·Journal of the American College of Cardiology·Tannas JateneUNKNOWN CHAMPION PHOENIX Investigators
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Sep 14, 2017·The New England Journal of Medicine·Satish K GargPaul Strumph
Jun 20, 2018·Lancet·Tejas PatelEileen E Navarro Almario
Aug 1, 2018·JACC. Basic to Translational Science·Stephen E ShermanSubodh Verma
Sep 29, 2018·Canadian Journal of Physiology and Pharmacology·Naresh KumarSubodh Verma
Oct 6, 2018·Journal of the American College of Cardiology·Sara B SeidelmannScott D Solomon
Nov 10, 2018·Journal of the American College of Cardiology·Muthiah VaduganathanDeepak L Bhatt
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Dec 6, 2018·Cell Metabolism·Kim A ConnellySubodh Verma
Jan 31, 2019·Lifetime Data Analysis·Per Kragh AndersenHenrik Ravn
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Jun 12, 2019·Circulation·Subodh Verma, Deepak L Bhatt
Sep 20, 2019·The New England Journal of Medicine·John J V McMurrayUNKNOWN DAPA-HF Trial Committees and Investigators
Nov 7, 2019·Cell Metabolism·Deepak L BhattEugene Braunwald
Dec 15, 2019·The Journal of Clinical Endocrinology and Metabolism·David R PowellPablo Lapuerta
Jan 26, 2020·Biochemical and Biophysical Research Communications·Biswajit ChowdhuryDavid A Hess
Mar 12, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Erika OpingariRichard E Gilbert
May 30, 2020·Journal of the American College of Cardiology·Emilia BagiellaMario Gaudino
Jul 28, 2020·Journal of the American Heart Association·Senthil SelvarajDeepak L Bhatt
Aug 4, 2020·Journal of the American College of Cardiology·Mario GaudinoEmilia Bagiella
Sep 1, 2020·The New England Journal of Medicine·Milton PackerUNKNOWN EMPEROR-Reduced Trial Investigators
Sep 3, 2020·Nature Reviews. Cardiology·Prakriti Gaba, Deepak L Bhatt
Sep 24, 2020·The New England Journal of Medicine·Christopher P CannonUNKNOWN VERTIS CV Investigators
Sep 25, 2020·The New England Journal of Medicine·Hiddo J L HeerspinkUNKNOWN DAPA-CKD Trial Committees and Investigators

❮ Previous
Next ❯

Citations

Nov 26, 2020·Nature Reviews. Cardiology·Andrew Robson
Jan 4, 2021·European Heart Journal·Héctor BuenoJohann Bauersachs
Jan 23, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Philip DüsingFelix Jansen
Feb 11, 2021·International Journal of Molecular Sciences·Mariusz Dąbrowski
Jan 27, 2021·The New England Journal of Medicine·Frank C Brosius, Per O Vandvik
Feb 12, 2021·Heart·Julio Alejandro Lamprea-MontealegreMichelle M Estrella
Dec 29, 2020·European Heart Journal. Cardiovascular Pharmacotherapy·Gianluigi Savarese
Jan 15, 2021·International Journal of Molecular Sciences·María Aguilar-BallesterHerminia González-Navarro
Feb 7, 2021·European Journal of Heart Failure·Gad CotterAlexandre Mebazaa
Mar 7, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Stefano CiardulloGianluca Perseghin
Mar 2, 2021·Frontiers in Cardiovascular Medicine·Qingchun ZengDingli Xu
Mar 9, 2021·Endocrinology and Metabolism·Eun-Jung RheeWon-Young Lee
Mar 12, 2021·Clinical Journal of the American Society of Nephrology : CJASN·Kathryn Larmour, Adeera Levin
Mar 27, 2021·Current Opinion in Nephrology and Hypertension·Caitlyn VlasschaertSamuel A Silver
Apr 2, 2021·Cardiovascular Diabetology·Oliver SchnellEberhard Standl
Apr 2, 2021·European Heart Journal·Hiddo J L HeerspinkUNKNOWN DAPA-CKD Trial Committees and Investigators
Mar 29, 2021·Néphrologie & thérapeutique·Jean-Michel Halimi
Mar 31, 2021·Metabolism Open·Natalia G VallianouMaria Dalamaga
Mar 30, 2021·European Journal of Heart Failure·Vibhu Parcha, Pankaj Arora
Apr 13, 2021·Advances in Therapy·Aileen KearneyIan B A Menown
Apr 15, 2021·The New England Journal of Medicine·Deepak L BhattBertram Pitt
Apr 15, 2021·The New England Journal of Medicine·Piero Baglioni
Apr 24, 2021·Circulation·Bertram Pitt, Deepak L Bhatt
Apr 20, 2021·Endocrinology and Metabolism·Jason F LeeDavid Z I Cherney
Mar 19, 2021·British Journal of Clinical Pharmacology·Paul G HunterNeeraj Dhaun
May 15, 2021·Journal of the American College of Cardiology·Lawrence A LeiterUNKNOWN THEMIS Steering Committee and Investigators
May 14, 2021·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Amr AbdinMichael Böhm
May 12, 2021·Korean Circulation Journal·Jaewon OhSeok Min Kang
May 25, 2021·Metabolism: Clinical and Experimental·Francesco PrattichizzoAntonio Ceriello

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Related Papers

The New England Journal of Medicine
Deepak L BhattSOLOIST-WHF Trial Investigators
The New England Journal of Medicine
Lucien MarchandLisa Green
The New England Journal of Medicine
Piero Baglioni
© 2021 Meta ULC. All rights reserved